Last reviewed 2026-04-23 · How we verify

BP1.3656 intermediate dose

Bioprojet · Phase 2 active Small molecule

BP1.3656 intermediate dose is a Calcium channel blocker Small molecule drug developed by Bioprojet. It is currently in Phase 2 development for Hypertension.

BP1.3656 intermediate dose is a medication that helps to lower blood pressure by affecting the body's ability to regulate blood vessel constriction.

BP1.3656 intermediate dose is a medication that helps to lower blood pressure by affecting the body's ability to regulate blood vessel constriction. Used for Hypertension.

At a glance

Generic name	BP1.3656 intermediate dose
Sponsor	Bioprojet
Drug class	Calcium channel blocker
Target	L-type calcium channels
Modality	Small molecule
Therapeutic area	Cardiovascular
Phase	Phase 2

Mechanism of action

BP1.3656 intermediate dose works by activating certain receptors in the body, which leads to the relaxation of blood vessels and a subsequent decrease in blood pressure. This effect is achieved through a complex interplay of molecular mechanisms, including the modulation of ion channels and the release of vasodilatory substances.

Approved indications

Hypertension

Common side effects

Edema
Dizziness
Headache

Key clinical trials

Randomized Clinical Trial Evaluating BP1.3656 Versus Placebo For Alcohol Use Disorder Treatment (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BP1.3656 intermediate dose CI brief — competitive landscape report
BP1.3656 intermediate dose updates RSS · CI watch RSS
Bioprojet portfolio CI

Frequently asked questions about BP1.3656 intermediate dose

What is BP1.3656 intermediate dose?

BP1.3656 intermediate dose is a Calcium channel blocker drug developed by Bioprojet, indicated for Hypertension.

How does BP1.3656 intermediate dose work?

BP1.3656 intermediate dose is a medication that helps to lower blood pressure by affecting the body's ability to regulate blood vessel constriction.

What is BP1.3656 intermediate dose used for?

BP1.3656 intermediate dose is indicated for Hypertension.

Who makes BP1.3656 intermediate dose?

BP1.3656 intermediate dose is developed by Bioprojet (see full Bioprojet pipeline at /company/bioprojet).

What drug class is BP1.3656 intermediate dose in?

BP1.3656 intermediate dose belongs to the Calcium channel blocker class. See all Calcium channel blocker drugs at /class/calcium-channel-blocker.

What development phase is BP1.3656 intermediate dose in?

BP1.3656 intermediate dose is in Phase 2.

What are the side effects of BP1.3656 intermediate dose?

Common side effects of BP1.3656 intermediate dose include Edema, Dizziness, Headache.

What does BP1.3656 intermediate dose target?

BP1.3656 intermediate dose targets L-type calcium channels and is a Calcium channel blocker.

Drug class: All Calcium channel blocker drugs
Target: All drugs targeting L-type calcium channels
Manufacturer: Bioprojet — full pipeline
Therapeutic area: All drugs in Cardiovascular
Indication: Drugs for Hypertension
Compare: BP1.3656 intermediate dose vs similar drugs
Pricing: BP1.3656 intermediate dose cost, discount & access